The CEO foresees a "snowball effect" of life sciences companies coming to Dallas, but a couple things need to happen first.

Michael Breen, CEO of GT Biopharma (GTBP), a clinical-stage biotech company, stressed that point with TheStreet Pro’s Chris ...

Cathie Wood’s ARK Invest executed a busy week of portfolio adjustments across its ETFs, with several high-conviction ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Read more here.

Unexpected delays, infighting and a staffing crisis are fueling investors’ unease.

Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...

RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking ...

A Nobel laureate, he identified an enzyme that cuts DNA, laying the groundwork for milestones in scientific research and ...

French biotech company Abivax SA started the year with a market value of less than $500 million. After a meteoric rally, it’s ...

Complete response (CR) observed in 70% (35/50) of patients with low-grade upper tract urothelial cancer (UTUC) who completed ...

A Pfizer-backed biotech landed $120M, embattled Kala Bio has secured a new CEO, and Akebia Therapeutics bought a rare kidney ...

NDAA package revives stalled measures on US outbound investment and biotech, signalling Capitol Hill’s hardened stance ...